ultim
goal
treatment
type
diabet
restor
physiolog
blood
glucos
regul
without
requir
lifelong
therapi
immunosuppress
immunoregul
numer
challeng
attain
goal
divers
approach
rang
insulin
pump
gene
therapi
stem
cell
strategi
anoth
approach
replac
lost
islet
cell
human
islet
allotransplant
establish
clinic
util
islet
although
human
islet
recipi
remain
year
major
patient
retain
graft
function
evidenc
persist
importantli
islet
transplant
larg
elimin
hypoglycem
unawar
improv
insulin
independ
like
data
select
institut
indic
increas
number
islet
recipi
approach
abl
maintain
extern
insulin
independ
nonetheless
avail
suitabl
human
pancreas
either
whole
organ
isol
islet
transplant
entir
inadequ
evidenc
recoveri
donor
pancreas
unit
state
use
xenogen
islet
could
provid
solut
limit
suppli
human
islet
transplant
porcin
islet
particularli
suitabl
sourc
cell
porcin
insulin
differ
human
insulin
singl
amino
acid
porcin
insulin
shown
provid
reliabl
safe
glycem
control
human
diabet
patient
furthermor
transplant
whole
pancrea
intact
islet
langerhan
expect
replic
normal
precis
physiolog
glucos
control
depend
varieti
cell
type
protein
pancreat
islet
enorm
complex
regulatori
machineri
absent
approach
normoglycemia
use
islet
tissu
howev
necessit
either
suppress
patient
immun
system
physic
isol
islet
prevent
reject
previous
describ
abil
encapsul
porcin
islet
function
diabet
anim
encapsul
islet
macrobead
least
partial
immun
isol
outer
layer
dens
agaros
prohibit
direct
cell
access
xenogen
islet
although
small
immun
mediat
cytokin
still
enter
macrobead
encapsul
approach
suffici
robust
allow
spontan
diabet
bb
rat
surviv
month
without
immunosuppress
without
exogen
insulin
ongo
studi
diabet
cynomolgu
macaqu
also
demonstr
porcin
islet
macrobead
function
month
anim
unpublish
data
see
checkpoint
clinic
use
islet
anim
also
requir
strategi
assur
microbiolog
safeti
anim
tissu
strategi
provid
asept
product
reduc
probabl
inadvert
transmiss
adventiti
virus
critic
success
implement
excit
therapi
approach
take
advantag
uniqu
aspect
islet
macrobead
name
viabil
cultur
lack
patient
immunosuppress
limit
microbiolog
safeti
risk
porcin
islet
transplant
essenti
approach
establish
four
checkpoint
span
macrobead
product
transplant
process
checkpoint
approach
built
upon
increas
level
microbiolog
screen
donor
herd
islet
product
use
multipl
assay
format
abil
screen
known
unknown
pathogen
use
checkpoint
approach
provid
evid
support
use
donor
anim
hous
high
hygien
environ
islet
xenotransplant
also
therapi
studi
present
document
effect
microbiolog
safeti
strategi
minim
microbiolog
risk
agaros
encapsul
porcin
islet
treatment
type
diabet
donor
pig
larg
white
yorkshir
landrac
hybrid
anim
obtain
modifi
choic
genet
formerli
newsham
sourc
anim
sourc
anim
facil
independ
own
herd
locat
rural
southwest
ohio
breed
herd
number
approxim
sow
util
quarantin
test
system
modern
multisit
product
strategi
three
segreg
facil
nurseri
gilt
isol
farrow
gestat
maintain
data
record
follow
standard
oper
procedur
sop
anim
husbandri
vaccin
hous
clean
wast
manag
biosecur
measur
control
transport
anim
suppli
semen
feed
water
pest
rodent
control
gravel
barrier
around
facil
perimet
caretak
qualif
includ
routin
health
assess
compon
comprehens
biosecur
program
routin
qualiti
assur
site
audit
use
verifi
complianc
pig
feed
produc
exclus
corn
grown
ground
onsit
sourc
anim
facil
gilt
gestat
sow
lactat
sow
given
base
feed
consist
corn
variou
supplement
eg
amino
acid
vitamin
miner
protein
slight
variat
base
breed
statu
anim
ingredi
use
product
complet
feed
certifi
free
restrict
use
protein
product
defin
fda
code
feder
regul
titl
part
cfr
pertain
cattl
materi
prohibit
anim
feed
complet
medic
histori
archiv
sourc
anim
facil
hold
pork
qualiti
assur
plu
pqa
certif
program
ensur
us
pork
product
highest
qualiti
pqa
plu
program
mandat
good
product
practic
emphasi
biosecur
practic
reduc
risk
introduc
spread
infecti
agent
retir
breed
sow
use
pancrea
donor
sent
local
abattoir
pork
product
sourc
anim
routin
vaccin
variou
agent
tabl
kill
vaccin
use
avail
modifi
live
viru
vaccin
use
evid
revers
virul
studi
parasail
prosystem
rce
kill
vaccin
avail
enterisol
ileiti
modifi
live
viru
vaccin
ingelvac
prr
except
vaccin
viru
found
one
studi
pig
contact
vaccin
altern
quarterli
kill
prr
vaccin
facil
oper
sourc
anim
health
screen
program
continu
assess
health
statu
herd
januari
decemb
screen
program
compos
random
antemortem
monthli
herd
test
sentinel
anim
program
includ
antemortem
postmortem
test
target
agent
test
method
sampl
type
monthli
sentinel
antemortem
screen
shown
tabl
sentinel
anim
program
consist
exclus
randomli
select
breed
sow
anim
hous
long
term
year
facil
blood
nasal
swab
fecal
sampl
collect
sentinel
anim
microbiolog
screen
gilt
select
nurseri
breed
first
quarantin
qualifi
introduct
gestat
facil
insid
breed
facil
breed
sow
age
candid
sentinel
program
train
boar
use
part
sentinel
program
elig
pancrea
donat
although
anim
part
routin
herd
health
screen
perform
monthli
follow
electr
stun
exsanguin
abattoir
complianc
feder
regul
concern
anim
handl
welfar
numer
tissu
includ
brain
heart
lung
liver
tonsil
lymph
node
spleen
ileum
kidney
pancrea
bone
marrow
pbmc
fece
serum
collect
archiv
fix
frozen
aliquot
time
pancrea
procur
aliquot
isol
islet
also
frozen
archiv
donor
anim
tissu
sampl
sent
univers
minnesota
veterinari
diagnost
laboratori
mvdl
screen
bacteri
viral
pathogen
list
tabl
mvdl
one
three
major
swine
diagnost
laboratori
unit
state
swine
veterinarian
use
mvdl
assay
monitor
heard
health
identifi
new
outbreak
infecti
diseas
laboratori
member
nation
anim
health
laboratori
network
nahln
usda
complet
qualif
report
assay
within
herd
health
program
perform
characterist
diagnost
assay
use
screen
sourc
anim
xenotransplant
submit
fda
part
investig
new
drug
ind
applic
use
encapsul
porcin
islet
treat
patient
type
diabet
qualif
report
contain
detail
inform
diagnost
assay
use
screen
sourc
anim
includ
assay
protocol
data
regard
sensit
specif
repeat
mvdl
assay
valid
accord
guidelin
establish
american
associ
veterinari
laboratori
diagnostician
standard
oper
procedur
avail
mvdl
upon
request
vdl
umnedu
detect
differ
target
agent
includ
follow
method
bacteri
cultur
transmiss
electron
microscopi
tem
immunohistochemistri
ihc
convent
quantit
polymeras
chain
reaction
pcr
qpcr
respect
quantit
revers
transcript
hemagglutin
inhibit
hi
serum
neutral
sn
viru
isol
vi
plaqu
reduct
neutral
test
prnt
addit
viru
isol
assay
perform
infect
suscept
cell
canin
kidney
mdck
cell
porcin
alveolar
macrophag
pam
primari
porcin
kidney
cell
ppk
porcin
kidney
cell
african
green
monkey
kidney
cell
bovin
turbin
cell
bt
look
unknown
porcin
virus
cell
type
cultur
presenc
tissu
homogen
brain
ileum
kidney
lung
liver
mesenter
lymph
node
spleen
tonsil
sentinel
anim
donor
anim
monitor
morpholog
chang
indic
viral
infect
prnt
test
eeev
veev
weev
wnv
occur
nation
veterinari
servic
laboratori
ame
ia
usa
donor
pancreas
procur
sow
year
age
histori
multipl
pariti
follow
electr
stun
exsanguin
donor
abdomin
viscera
retriev
technician
transfer
steril
contain
transport
viscera
place
custom
built
laminar
flow
work
station
tissu
retriev
surfac
monitor
perform
work
surfac
prior
retriev
settl
plate
place
insid
workstat
dissect
monitor
microbiolog
contamin
intact
pancrea
dissect
viscera
technician
immedi
transfer
cold
hbss
cellgro
manassa
va
usa
tissu
submers
cold
solut
veton
bois
id
usa
follow
two
submers
rins
cold
hbss
pancrea
transport
islet
isol
laboratori
steril
contain
submerg
cold
hbss
contain
transfer
biolog
safeti
cabinet
pancrea
remov
transport
media
sampl
collect
total
bioburden
test
avista
pharma
solut
inc
agawam
usa
warm
ischemia
time
begin
exsanguin
pancrea
immers
cold
transport
solut
rang
minut
cold
ischemia
time
pancrea
immers
cold
transport
solut
placement
digest
chamber
rang
minut
pancreas
perfus
wunsch
ug
collagenas
collagenas
vitacyt
indianapoli
usa
neutral
proteas
ug
pancrea
bp
proteas
vitacyt
mgpancrea
pulmozym
genentech
south
san
francisco
ca
usa
solut
prepar
cold
storag
purif
stock
solut
cellgro
islet
count
express
islet
equival
ieq
base
standard
islet
size
ieq
encapsul
macrobead
previous
follow
quantif
islet
separ
ieq
aliquot
resuspend
ml
wv
seakem
gold
agaros
deriv
gelidium
speci
seawe
lonza
rockland
inc
rockland
md
usa
prepar
minim
essenti
medium
plu
mmol
l
hepe
buffer
st
loui
mo
usa
suspens
expel
beneath
surfac
steril
miner
oil
produc
four
spheric
bead
approxim
mm
diamet
contain
ieq
coat
macrobead
cultur
humidifi
atmospher
day
second
coat
seakem
gold
agaros
appli
give
macrobead
final
diamet
mm
determin
averag
pore
size
agaros
macrobead
difficult
best
given
gelat
mechan
random
polym
coil
form
aggreg
doubl
helic
result
pore
variou
diamet
wall
reason
macrobead
consid
provid
absolut
viral
sequestr
although
encapsul
islet
protect
direct
immun
cell
contact
agaras
enzym
necessari
break
agaros
abund
bacteria
found
macrobead
absenc
trauma
remain
intact
indefinit
follow
implant
abdomin
caviti
macrobead
cultur
humidifi
atmospher
collect
microbiolog
screen
implant
cultur
medium
rpmi
life
technolog
grand
island
ny
usa
endotoxin
euml
steril
contain
mmoll
glucos
porcin
serum
biologo
montgomeri
il
usa
steril
absenc
mycoplasma
adventiti
virus
per
endotoxin
euml
life
technolog
chang
weekli
media
sampl
taken
porcin
insulin
elisa
assay
mercodia
uppsala
sweden
islet
isol
encapsul
procedur
perform
class
ii
biosafeti
cabinet
within
iso
class
rest
iso
class
activ
process
laboratori
technician
routin
environment
monitor
includ
particl
count
viabl
particl
count
settl
plate
surfac
monitor
perform
everi
islet
isol
procedur
macrobead
given
donor
assign
uniqu
islet
isol
number
cultur
separ
islet
macrobead
produc
donor
anim
viral
screen
islet
macrobead
perform
sg
vitrolog
glasgow
uk
group
extens
experi
approxim
year
test
islet
macrobead
cancer
macrobead
see
discuss
essenti
develop
viral
screen
program
product
repres
macrobead
seal
steril
screw
top
tube
frozen
ship
dri
ice
sg
vitrolog
screen
use
molecular
vitro
assay
shipment
receiv
releas
offic
scottish
execut
rural
director
follow
appropri
content
import
licens
verif
aliquot
islet
macrobead
rather
isol
free
islet
select
screen
insur
potenti
viral
activ
due
stress
encapsul
procedur
account
similar
aliquot
also
frozen
archiv
possibl
futur
investig
use
pcr
assay
dna
extract
macrobead
pool
individu
donor
two
macrobead
per
donor
homogen
buffer
atl
qiagen
valencia
ca
usa
lysi
adsorpt
silica
membran
qiagen
rneasi
kit
use
rna
extract
accord
manufactur
instruct
viral
rna
dna
extract
method
pcr
assay
valid
ich
guidelin
test
carri
valid
assay
pcr
test
perform
complianc
describ
ph
eur
usp
figur
reaction
contain
islet
cell
equival
qpcr
islet
cell
equival
vitro
assay
detect
adventiti
viru
contamin
perform
follow
six
islet
macrobead
per
donor
sampl
cultur
medium
use
gener
test
sampl
test
materi
thaw
supernat
retain
macrobead
ground
steril
tissu
grinder
taken
two
cycl
freez
thaw
ground
bead
mix
cultur
supernat
pool
materi
filter
filter
remov
larg
debri
clarifi
centrifug
clarifi
supernat
materi
use
lysat
sampl
inocul
four
indic
cell
line
consist
human
lung
fetal
fibroblast
cell
babi
hamster
kidney
cell
swine
testi
cell
st
african
green
monkey
kidney
cell
inocul
test
sampl
incub
monitor
period
least
day
develop
cytopath
effect
cpe
neg
control
includ
monitor
health
indic
cell
line
tissu
cultur
medium
throughout
vitro
assay
cytopath
cpe
viru
posit
control
inocul
day
test
sampl
includ
indic
cell
line
cell
inocul
herp
simplex
viru
type
cell
inocul
emcv
st
cell
inocul
ppv
cell
inocul
posit
control
virus
inocul
unitsvessel
end
assay
neg
control
tissu
cultur
medium
posit
control
influenza
viru
hemadsorpt
ha
assay
includ
qualifi
red
blood
cell
prepar
use
pool
guinea
pig
chicken
human
type
red
blood
cell
control
inocul
onto
separ
batch
indic
cell
nearer
end
assay
transmiss
electron
microscopi
tem
perform
use
glutaraldehyd
fix
islet
cell
macrobead
cell
osmium
tetroxid
stain
en
bloc
uranyl
acet
dehydr
ethanol
seri
propylen
oxid
infiltr
araldit
resin
polymer
section
cut
mount
glass
slide
stain
toluidin
blue
examin
light
microscopi
gener
qualiti
fixat
gross
cell
morpholog
presenc
mitot
cell
dead
die
cell
cultur
ultrathin
section
cut
mount
electron
microscop
grid
stain
uranyl
acet
lead
citrat
solut
minimum
median
cell
profil
examin
presenc
virus
particl
extran
agent
ultra
structur
morpholog
cell
also
record
prior
islet
macrobead
implant
repres
sampl
macrobead
sent
steril
test
per
usp
ph
eur
via
membran
filtrat
addit
assess
presenc
mycoplasma
use
direct
indic
cell
cultur
method
usp
ph
eur
mycoplasma
test
avista
pharma
solut
inc
agawam
usa
macrobead
also
screen
presenc
bacteri
endotoxin
per
usp
ph
eur
microbiolog
test
steril
endotoxin
mycoplasma
repeat
week
prior
implant
well
prior
implant
six
diabet
male
cynomolgu
macaqu
mauritian
asian
origin
median
age
year
rang
year
median
bodi
weight
kg
rang
kg
receiv
mean
porcin
islet
macrobead
implant
intraperiton
day
correspond
mean
islet
equival
per
anim
six
anim
receiv
second
dose
mean
islet
macrobead
day
first
transplant
correspond
mean
islet
equival
per
anim
blood
sampl
pbmc
isol
collect
prior
schedul
interv
subsequ
pcr
analysi
determin
potenti
porcin
viral
transmiss
includ
pcv
plhv
prrsv
pcmv
infect
time
point
evalu
month
day
month
day
addit
sampl
year
day
year
day
year
day
evalu
subset
recipi
reach
time
point
extend
procedur
anim
approv
univers
minnesota
institut
anim
care
use
committe
conduct
complianc
anim
welfar
act
adher
principl
state
guid
care
use
laboratori
anim
multipl
checkpoint
process
porcin
islet
isol
encapsul
cultur
transplant
implement
assess
microbiolog
safeti
islet
macrobead
figur
health
statu
anim
sourc
anim
facil
maintain
high
level
continu
evalu
use
monthli
health
check
randomli
select
anim
util
sentinel
anim
program
select
anim
locat
throughout
facil
act
environment
monitor
extens
repeat
screen
monthli
screen
randomli
select
anim
year
presenc
antibodi
prrsv
confirm
efficaci
vaccin
program
prrsv
given
absenc
prrsv
rna
sentinel
donor
anim
screen
tabl
antibodi
also
routin
detect
prcv
demonstr
widespread
preval
viru
donor
anim
facil
neg
presenc
tgev
screen
introduct
viru
use
continu
document
biosecur
sourc
anim
facil
one
posit
find
sampl
consid
fals
posit
given
absenc
posit
find
quarterli
antemortem
screen
result
sentinel
anim
also
demonstr
efficaci
vaccin
program
overal
herd
health
evidenc
posit
find
antibodi
ppv
prrsv
sampl
part
vaccin
program
evid
influenza
viru
monitor
presenc
rna
also
part
vaccin
program
nasal
swab
sampl
tabl
addit
result
sentinel
anim
includ
posit
identif
fecal
sampl
bacteriophagepicornaviridaecaudoviral
fece
use
electron
microscopi
antibodi
prcv
found
serum
sampl
total
result
consid
suspect
equin
encephalomyel
virus
venezuelan
western
eastern
owe
viru
growth
variat
interpret
low
dilut
factor
result
assay
seven
posit
result
emcv
assay
four
find
salmonella
spp
fece
also
report
numer
tissu
collect
sentinel
donor
anim
sacrific
viral
screen
mvdl
postmortem
viral
screen
six
sentinel
anim
pancrea
donor
anim
yield
posit
result
sampl
exclud
virus
part
vaccin
program
three
perv
subtyp
sampl
screen
assay
tabl
presenc
enter
virus
detect
sentinel
anim
coronavirida
n
caudoviral
n
small
round
viral
particl
observ
identifi
fece
pancreat
donor
anim
bacteriophag
identifi
pancrea
donor
anim
test
posit
find
observ
fece
three
sentinel
anim
test
screen
phev
antibodi
yield
posit
find
sentinel
anim
pancrea
donor
anim
screen
discontinu
sourc
anim
viru
shown
ubiquit
pig
herd
public
health
signific
given
pig
known
six
posit
result
observ
three
equin
encephalomyel
virus
consid
result
given
low
dilut
factor
report
df
singl
posit
result
report
antibodi
tgev
postmortem
serum
sampl
sentinel
anim
antemortem
serum
anim
consist
neg
immunohistochemistri
stain
ileum
also
neg
presenc
phov
sequenc
pcr
analysi
detect
sentinel
donor
anim
pancreas
lymph
node
sampl
subsequ
assess
isol
porcin
islet
evid
viru
evid
viral
transmiss
observ
six
differ
cell
line
four
speci
use
tissu
homogen
sampl
sentinel
donor
anim
given
evid
satisfactori
insulin
product
cultur
islet
macrobead
macrobead
sent
viral
screen
sg
vitrolog
prior
use
anim
studi
islet
macrobead
neg
virus
screen
pcr
n
virus
assay
use
four
differ
suscept
cell
line
n
pancrea
donor
anim
tabl
transmiss
scan
electron
microscopi
incorpor
addit
viral
screen
tool
virus
particl
extran
agent
includ
mycoplasma
yeast
fungi
bacteria
found
pancrea
donor
compris
two
macrobead
lot
produc
tabl
figur
condit
media
sampl
taken
week
encapsul
neg
bacteri
growth
presenc
endotoxin
mycoplasma
tabl
although
sourc
materi
product
releas
screen
recipi
monitor
implant
provid
valuabl
data
could
use
treat
individu
patient
also
check
efficaci
possibl
modif
checkpoint
import
compon
thorough
safeti
program
exampl
islet
macrobead
recipi
monitor
diabet
cynomolgu
macaqu
receiv
porcin
islet
macrobead
implant
routin
monitor
graft
function
evid
viral
transmiss
andor
infect
five
anim
implant
shown
measur
clinic
benefit
term
reduc
exogen
insulin
requir
approxim
reduct
design
model
propos
phase
ind
trial
improv
andor
stabl
blood
glucos
read
level
year
signific
advers
event
observ
anim
date
bodi
weight
remain
stabl
increas
anim
line
overal
health
anim
screen
select
virus
perform
mvdl
base
presenc
viru
sourc
herd
pcv
type
virus
uncertain
herd
statu
prrsv
virus
concern
given
similar
infecti
human
virus
activ
pig
immunosuppress
primat
xenotransplant
pcmv
respect
isol
peripher
blood
mononuclear
cell
time
point
neg
pcv
type
prrsv
pcmv
pcr
analysi
tabl
moreov
evid
viral
infect
observ
document
health
statu
anim
microbiolog
safeti
program
outlin
util
four
separ
assess
microbiolog
safeti
agaros
encapsul
porcin
islet
occur
sequenti
sourc
anim
herd
individu
donor
anim
intend
transplant
product
final
recipi
follow
implant
donor
herd
design
sentinel
anim
pancrea
donor
anim
islet
macrobead
extens
screen
exclud
latent
adventiti
contamin
encapsul
method
support
islet
viabil
extend
cultur
period
permit
ampl
time
conduct
numer
screen
assay
detect
specif
virus
electron
microscop
detect
viral
particl
andor
cell
damag
lengthi
vitro
cultur
screen
known
unknown
virus
signific
advanc
indirect
test
anim
rais
gnotobiot
condit
allow
screen
multipl
point
throughout
islet
macrobead
manufactur
process
final
sampl
patient
implant
porcin
islet
macrobead
screen
evid
xenozoonosi
use
valid
assay
similar
employ
sentinel
donor
anim
macrobead
test
part
surveil
program
integr
safeti
program
develop
help
numer
scientist
clinician
expert
veterinari
care
toxicolog
qualiti
assur
veterinari
diagnost
islet
isol
clinic
medicin
microbiolog
virolog
program
evolv
adventiti
agent
screen
assess
use
vaccin
biotechnolog
product
describ
usp
ph
eur
ich
guidelin
certain
adapt
made
due
natur
sampl
type
product
abil
program
ensur
health
statu
donor
anim
high
islet
macrobead
consist
neg
bacteri
viral
contamin
firmli
establish
safeti
program
open
continu
review
refin
consult
relev
expert
throughout
world
exampl
use
transmiss
electron
microscopi
tem
provid
addit
screen
islet
macrobead
known
unknown
virus
extran
agent
recent
implement
routin
appli
vaccin
product
even
though
tem
consider
lower
sensit
compar
pcr
posit
tem
find
investig
identifi
known
agent
use
immunohistochemistri
molecular
techniqu
involv
variou
specialist
extend
beyond
develop
microbiolog
safeti
program
encourag
continu
program
improv
regular
meet
exampl
could
prompt
addit
new
virus
concern
ad
screen
panel
newoptim
procedur
anim
husbandri
clinic
care
could
implement
specialist
guidanc
unit
state
food
drug
administr
fda
regulatori
respons
somat
cell
therapi
includ
xenogen
cell
therefor
porcin
fda
center
biolog
evalu
research
cber
regul
biolog
product
includ
cell
therapi
releas
final
guidanc
industri
regard
xenotransplant
product
european
medicin
agenc
ema
overse
advanc
therapi
medicin
product
atmp
includ
cell
transplant
world
health
well
intern
confer
also
issu
xenotransplant
guidanc
intern
xenotransplant
associ
ixa
recent
publish
first
updat
origin
consensu
statement
use
porcin
islet
clinic
focu
guidelin
includ
ixa
statement
safeti
invit
review
us
xenogen
regul
publish
fda
staff
provid
addit
detail
fda
schuurman
recent
publish
thorough
overview
worldwid
xenogen
regul
emphasi
european
microbiolog
safeti
program
issu
consider
fda
xenotransplant
guidelin
well
ixa
statement
regard
donor
anim
import
note
guidelin
state
sourc
anim
must
rais
environ
signific
addit
difficulti
obtain
maintain
guarante
pancrea
individu
anim
suitabl
islet
isol
fact
becom
increas
clear
porcin
pancreas
yield
suffici
number
islet
clinic
given
limit
approach
rais
sourc
anim
high
hygien
environ
biopsi
individu
pancreas
islet
isol
suitabl
perform
extens
microbiolog
screen
select
donor
anim
tissu
islet
macrobead
methodolog
howev
employ
altern
approach
quarantin
period
individu
donor
anim
deserv
discuss
minimum
quarantin
period
anim
use
process
biolog
product
also
state
cfr
part
rational
quarantin
period
provid
time
acut
infect
becom
clinic
quarantin
period
cohort
anim
would
hous
environ
strict
husbandri
practic
design
elimin
introduct
adventiti
agent
similar
laboratori
specif
spf
anim
facil
anim
would
monitor
develop
diseas
symptom
undergo
blood
fecal
nasal
swab
sampl
microbiolog
statu
assess
develop
diseas
symptom
unsatisfactori
diagnost
result
anim
would
disqualifi
anim
given
cohort
pancrea
donat
donor
qualif
process
appropri
suffici
time
perform
thorough
screen
islet
transplant
exampl
free
islet
transplant
within
day
isol
islet
encapsul
agaros
macrobead
contrast
surviv
year
vitro
allow
ampl
time
conduct
numer
lengthi
assay
design
detect
known
unknown
microbiolog
agent
assay
screen
islet
product
directli
like
detect
patholog
agent
assess
clinic
condit
donor
may
present
diseas
symptom
eg
ppv
detect
latent
viru
eg
plhv
might
readili
observ
particular
organ
reliabl
peripher
blood
thu
islet
macrobead
tissu
implant
undergo
quarantin
abil
thoroughli
screen
islet
use
wide
varieti
specif
assay
obviat
need
rais
quarantin
donor
anim
environ
discuss
schuurman
first
ixa
consensu
statement
sourc
anim
suggest
longer
time
period
islet
cell
cultur
relev
health
statu
sourc
pig
becom
less
focu
dpf
statu
cultur
cell
ideolog
reflect
first
updat
ixa
consensu
statement
relat
encapsul
islet
allow
time
necessari
thorough
microbi
screen
potenti
move
safeti
criteria
toward
design
support
use
anim
spent
adult
life
high
biosecur
facil
employ
husbandri
practic
provid
donor
anim
high
health
use
asept
techniqu
standard
oper
procedur
procur
pancrea
isol
encapsul
islet
ensur
freedom
adventiti
viru
contamin
microbiolog
safeti
program
present
screen
numer
tissu
pancrea
donor
sentinel
anim
pathogen
combin
use
media
porcin
serum
approach
control
major
rout
introduct
adventiti
agent
could
enter
macrobead
product
process
emphasi
checkpoint
monitor
sourc
herd
provid
inform
potenti
break
biosecur
may
warrant
addit
test
temporari
halt
macrobead
product
checkpoint
also
true
individu
donor
anim
screen
case
may
necessit
discard
macrobead
produc
suspect
tissu
checkpoint
posit
viral
find
macrobead
except
perv
would
automat
result
destruct
macrobead
checkpoint
final
patient
monitor
checkpoint
provid
valuabl
inform
potenti
treatment
option
case
suspect
pathogen
transmiss
also
manufactur
decis
well
feedback
checkpoint
may
result
modif
one
checkpoint
medic
procedur
alway
risk
transplant
porcin
islet
challeng
face
understand
risk
minim
accept
level
light
expect
clinic
benefit
potenti
risk
viral
transfer
transplant
cell
recipi
major
safeti
concern
address
issu
test
rational
develop
screen
sentinel
donor
anim
virus
present
herd
special
interest
known
zoonot
agent
known
infect
swine
usa
initi
character
perv
infect
statu
sourc
herd
perform
given
unlik
abil
least
time
elimin
endogen
retrovirus
grow
conclus
risk
perv
transmiss
human
xenotransplant
trial
particip
virus
exclud
screen
date
known
present
unit
state
eg
japanes
enceph
viru
unlik
present
sourc
facil
eg
vesicular
exanthema
swine
viru
unlik
found
pancrea
surviv
extend
macrobead
cultur
porcin
toroviru
mani
screen
exclus
criteria
appli
infecti
agent
eg
toxoplasma
gondii
unlik
present
biosecur
sourc
herd
similar
rational
use
pathogen
screen
report
wynyard
et
al
auckland
island
strain
agent
present
uncertain
statu
new
zealand
relev
biosecur
facil
infecti
potenti
abil
agent
surviv
environ
pancrea
use
develop
list
screen
pathogen
herd
origin
anim
isol
remot
island
south
new
zealand
may
consid
dpf
routin
screen
document
free
specif
infecti
bacteria
fungi
protozoa
virus
although
rational
behind
develop
pathogen
list
similar
approach
applic
screen
program
differ
ultim
new
zealand
group
test
sourc
anim
coloni
virus
bacteri
speci
one
protozoa
reduc
number
pathogen
screen
donor
piglet
islet
prepar
minipig
herd
ellegaard
denmark
also
qualifi
dpf
sourc
anim
facil
anim
shown
free
least
infecti
agent
includ
virus
pcr
methodolog
one
except
find
swine
hepat
e
viru
pair
anim
one
year
data
suggest
case
may
possibl
select
donor
anim
base
viral
profil
individu
anim
approach
favor
routin
screen
donor
herd
greater
emphasi
screen
sentinel
donor
anim
even
greater
emphasi
place
qualif
islet
macrobead
checkpoint
increas
number
virus
screen
use
varieti
assay
includ
specif
pcr
method
addit
electron
microscopi
assay
employ
look
unknown
virus
would
prompt
effort
identifi
viru
either
known
unknown
agent
eg
prrsv
induc
cpe
cell
one
compon
islet
macrobead
screen
also
part
releas
criteria
islet
macrobead
confirm
steril
free
mycoplasma
signific
level
endotoxin
although
current
paper
report
porcin
islet
macrobead
screen
result
previou
year
found
evid
presenc
known
unknown
transmiss
virus
islet
macrobead
screen
porcin
pancreat
islet
isol
donor
anim
previou
year
moreov
evid
xenogen
infect
found
numer
tissu
anim
implant
islet
macrobead
new
emerg
virus
routin
investig
optim
screen
variou
checkpoint
exampl
presenc
phov
also
known
porcin
partetraviru
nucleotid
sequenc
investig
sourc
anim
islet
macrobead
date
viru
cultur
isol
evid
exist
find
genom
found
evid
phov
sequenc
variou
porcin
tissu
includ
pancrea
mesenter
lymph
node
donor
serum
frozen
vendor
suppli
porcin
serum
use
islet
isol
macrobead
cultur
sequenc
found
purifi
islet
isol
absenc
porcin
serum
also
detect
sequenc
domest
intern
porcin
serum
sourc
phov
screen
islet
macrobead
cultur
sera
postpon
suitabl
sourc
could
obtain
regard
perv
identif
viru
abil
cross
speci
barrier
princip
concern
porcin
xenotransplant
worth
mention
nhp
ideal
model
assess
risk
perv
transmiss
cynomolgu
monkey
lack
receptor
major
receptor
actual
risk
perv
infect
clinic
remain
unclear
far
transmiss
perv
porcin
microorgan
human
expos
pig
islet
consid
find
well
neg
viral
find
diabet
dog
expos
porcin
islet
macrobead
year
evid
viral
transmiss
follow
macrobead
implant
low
studi
canin
cell
shown
cell
appar
degre
human
thu
may
question
relev
dog
model
perv
transmiss
studi
although
canin
cell
subject
suscept
porcin
virus
includ
among
other
risk
patient
also
exist
must
consid
part
comprehens
safeti
evalu
includ
procedur
risk
accompani
screen
well
gener
anesthesia
laparoscop
surgeri
requir
implant
macrobead
procedur
risk
well
known
although
real
modest
implant
cancer
macrobead
encapsul
mous
renal
adenocarcinoma
cell
treat
patient
variou
malign
year
without
advers
event
attribut
macrobead
either
intraperiton
irrit
microbiolog
see
also
clinicaltrialsgov
identifi
final
import
consider
immun
statu
recipi
recent
progress
clinic
islet
allotransplant
confirm
potenti
islet
graft
reduc
exogen
insulin
administr
occurr
hypoglycem
result
encourag
numer
advers
event
includ
intrahepat
bleed
neutropenia
mouth
ulcer
anemia
diarrhea
edema
hypercholesterolemia
pharyng
report
advers
event
primarili
associ
immunosuppress
therapi
encapsul
porcin
islet
use
method
elimin
need
immunosuppress
therapi
fulli
compet
immun
system
expect
significantli
reduc
risk
xenozoonot
likewis
gener
agre
modifi
sourc
anim
reduc
risk
zoonot
infect
unmodifi
viral
particl
would
like
activ
human
diabet
nhp
surveil
evid
viral
infect
pcv
type
prrsv
pcmv
perv
sampl
collect
longitudin
togeth
data
demonstr
reduc
risk
absenc
immunosuppress
suggest
viral
safeti
profil
accept
agaros
encapsul
porcin
islet
last
year
understand
risk
associ
porcin
xenotransplant
methodolog
manag
risk
includ
theoret
risk
potenti
presenc
unknown
pathogen
significantli
progress
recent
ixa
consensu
updat
note
theoret
risk
still
exist
relat
transmiss
infecti
agent
employ
appropri
safeguard
event
like
rare
although
actual
risk
islet
xenotransplant
known
absenc
clinic
trial
state
fishman
clinic
xenotransplant
level
safeti
develop
beyond
avail
human
islet
xenotransplant
point
clinic
trial
unit
state
europ
consid
light
expect
patient
benefit
one
particularli
import
benefit
base
preclin
anim
studi
islet
transplant
gener
like
reduct
glycem
excurs
life
threaten
experienc
often
patient
hypoglycem
unawar
microbiolog
safeti
program
present
screen
comprehens
set
tissu
pancrea
donor
sentinel
anim
numer
infecti
agent
combin
macrobead
screen
assay
provid
unparallel
level
safeti
result
support
use
multicheckpoint
biolog
safeti
program
screen
encapsul
porcin
islet
intend
clinic
trial
treatment
hypoglycem
unawar
unstabl
diseas
patient
type
diabet
lsg
jc
al
mjm
dg
hvv
mmm
dh
sr
rdh
bh
perform
conceptdesign
lsg
jc
al
rwh
dg
mg
mal
dgm
bh
perform
critic
revis
articl
rwh
mal
cm
jb
ewm
dgm
mmm
perform
data
collectionorgan
author
perform
data
analysisinterpret
draft
articl
approv
articl
